EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $419 | $876 | $131 | $352 |
| - Cash | $100 | $281 | $96 | $179 |
| + Debt | $22 | $5 | $46 | $39 |
| Enterprise Value | $342 | $600 | $81 | $213 |
| Revenue | $43 | $46 | $41 | $37 |
| % Growth | -6% | 11.1% | 12.1% | – |
| Gross Profit | $40 | $41 | $33 | $29 |
| % Margin | 91.4% | 89.9% | 79.9% | 77.9% |
| EBITDA | -$129 | -$69 | -$97 | -$50 |
| % Margin | -298.6% | -149.9% | -233.4% | -135.8% |
| Net Income | -$131 | -$71 | -$102 | -$58 |
| % Margin | -302.4% | -153.8% | -247% | -158.1% |
| EPS Diluted | -2.32 | -1.82 | -2.74 | -2.03 |
| % Growth | -27.5% | 33.6% | -35% | – |
| Operating Cash Flow | -$126 | $2 | -$65 | -$50 |
| Capital Expenditures | -$4 | -$3 | -$2 | -$0 |
| Free Cash Flow | -$130 | -$2 | -$67 | -$50 |